This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tisdale, M.
Right arrow Articles by Blair, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tisdale, M.
Right arrow Articles by Blair, E. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Aug 1995, 1704-1710, Vol 39, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

M Tisdale, RE Myers, B Maschera, NR Parry, NM Oliver and ED Blair
Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.

Human immunodeficiency virus type 1 (HIV-1) protease inhibitor- resistant variants, isolated on passage of HIV-1HXB2 in MT-4 cells with five different protease inhibitors, have been examined for cross- resistance to five inhibitors. The protease inhibitors studied were Ro 31-8959, A-77003, XM323, L-735,524, and VX-478. Resistant variants with two to four mutations within their protease sequence and 9- to 40-fold- decreased susceptibility were selected for all five inhibitors within six to eight passes in cell culture. Passage of a zidovudine-resistant mutant in Ro 31-8959 generated a dual reverse transcriptase- and protease-resistant virus. Variants were cloned directly into a modified pHXB2-D infectious clone for cross-resistance analysis. Although the resistant variants selected possessed different combinations of protease mutations for each inhibitor, many showed cross-resistance to the other inhibitors, and one showed cross-resistance to all five inhibitors. Interestingly, some mutants showed increased susceptibility to some inhibitors. Further HIV passage studies in the combined presence of two protease inhibitors demonstrated that in vitro it was possible to delay significantly selection of mutations producing resistance to one or both inhibitors. These studies indicate that there may be some rationale for combining different protease inhibitors as well as protease and reverse transcriptase inhibitors in HIV combination therapy.


This article has been cited by other articles:

  • Dekhtyar, T., Ng, T. I., Lu, L., Masse, S., DeGoey, D. A., Flosi, W. J., Grampovnik, D. J., Klein, L. L., Kempf, D. J., Molla, A. (2008). Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742. Antimicrob. Agents Chemother. 52: 1337-1344 [Abstract] [Full Text]  
  • Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774 [Abstract] [Full Text]  
  • Hester, E K., Chandler, H. V, Sims, K. M (2006). Fosamprenavir: Drug Development for Adherence. The Annals of Pharmacotherapy 40: 1301-1310 [Abstract] [Full Text]  
  • Weinheimer, S., Discotto, L., Friborg, J., Yang, H., Colonno, R. (2005). Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones. Antimicrob. Agents Chemother. 49: 3816-3824 [Abstract] [Full Text]  
  • Singh, R. A. K., Barry, M. A. (2004). Repertoire and Immunofocusing of CD8 T Cell Responses Generated by HIV-1 gag-pol and Expression Library Immunization Vaccines. J. Immunol. 173: 4387-4393 [Abstract] [Full Text]  
  • Scudeller, L., Torti, C., Quiros-Roldan, E., Patroni, A., Lo Caputo, S., Moretti, F., Mazzotta, F., Donati, E., Vivarelli, A., Carosi, G., on behalf of the GenPheRex Group of the MASTER Coh, (2003). HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. J Antimicrob Chemother 52: 776-781 [Abstract] [Full Text]  
  • Goodenow, M. M., Rose, S. L., Tuttle, D. L., Sleasman, J. W. (2003). HIV-1 fitness and macrophages. J. Leukoc. Biol. 74: 657-666 [Abstract] [Full Text]  
  • Paulsen, D., Elston, R., Snowden, W., Tisdale, M., Ross, L. (2003). Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J Antimicrob Chemother 52: 319-323 [Full Text]  
  • Watkins, T., Resch, W., Irlbeck, D., Swanstrom, R. (2003). Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 47: 759-769 [Abstract] [Full Text]  
  • Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]  
  • Maguire, M. F., Guinea, R., Griffin, P., Macmanus, S., Elston, R. C., Wolfram, J., Richards, N., Hanlon, M. H., Porter, D. J. T., Wrin, T., Parkin, N., Tisdale, M., Furfine, E., Petropoulos, C., Snowden, B. W., Kleim, J.-P. (2002). Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro. J. Virol. 76: 7398-7406 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Maguire, M., Shortino, D., Klein, A., Harris, W., Manohitharajah, V., Tisdale, M., Elston, R., Yeo, J., Randall, S., Xu, F., Parker, H., May, J., Snowden, W. (2002). Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors. Antimicrob. Agents Chemother. 46: 731-738 [Abstract] [Full Text]  
  • Yusa, K., Song, W., Bartelmann, M., Harada, S. (2002). Construction of a Human Immunodeficiency Virus Type 1 (HIV-1) Library Containing Random Combinations of Amino Acid Substitutions in the HIV-1 Protease due to Resistance by Protease Inhibitors. J. Virol. 76: 3031-3037 [Abstract] [Full Text]  
  • La Seta Catamancio, S., De Pasquale, M. P., Citterio, P., Kurtagic, S., Galli, M., Rusconi, S. (2001). In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure. J. Clin. Microbiol. 39: 1124-1129 [Abstract] [Full Text]  
  • Gilbert, P. B., DeGruttola, V., Hammer, S. M., Kuritzkes, D. R. (2001). Virologic and Regimen Termination Surrogate End Points in AIDS Clinical Trials. JAMA 285: 777-784 [Abstract] [Full Text]  
  • Gong, Y.-F., Robinson, B. S., Rose, R. E., Deminie, C., Spicer, T. P., Stock, D., Colonno, R. J., Lin, P.-f. (2000). In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632. Antimicrob. Agents Chemother. 44: 2319-2326 [Abstract] [Full Text]  
  • Markland, W., Rao, B. G., Parsons, J. D., Black, J., Zuchowski, L., Tisdale, M., Tung, R. (2000). Structural and Kinetic Analyses of the Protease from an Amprenavir-Resistant Human Immunodeficiency Virus Type 1 Mutant Rendered Resistant to Saquinavir and Resensitized to Amprenavir. J. Virol. 74: 7636-7641 [Abstract] [Full Text]  
  • Martínez, M.-A., Cabana, M., Parera, M., Gutierrez, A., Esté, J. A., Clotet, B. (2000). A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease. Antimicrob. Agents Chemother. 44: 1132-1139 [Abstract] [Full Text]  
  • Rusconi, S., La Seta Catamancio, S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., d'Arminio-Monforte, A. (2000). Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 1328-1332 [Abstract] [Full Text]  
  • Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., Whitcomb, J. M. (2000). A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 44: 920-928 [Abstract] [Full Text]  
  • Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., Markowitz, M. (1999). HIV-1 Drug Resistance in Newly Infected Individuals. JAMA 282: 1135-1141 [Abstract] [Full Text]  
  • Bossi, P., Mouroux, M., Yvon, A., Bricaire, F., Agut, H., Huraux, J.-M., Katlama, C., Calvez, V. (1999). Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor. J. Clin. Microbiol. 37: 2910-2912 [Abstract] [Full Text]  
  • Boden, D., Markowitz, M. (1998). Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 42: 2775-2783 [Full Text]  
  • Patick, A. K., Potts, K. E. (1998). Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev. 11: 614-627 [Abstract] [Full Text]  
  • Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M. R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D. R., Markowitz, M. (1998). Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir. Antimicrob. Agents Chemother. 42: 2637-2644 [Abstract] [Full Text]  
  • Carrillo, A., Stewart, K. D., Sham, H. L., Norbeck, D. W., Kohlbrenner, W. E., Leonard, J. M., Kempf, D. J., Molla, A. (1998). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor. J. Virol. 72: 7532-7541 [Abstract] [Full Text]  
  • Eastman, P. S., Mittler, J., Kelso, R., Gee, C., Boyer, E., Kolberg, J., Urdea, M., Leonard, J. M., Norbeck, D. W., Mo, H., Markowitz, M. (1998). Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy. J. Virol. 72: 5154-5164 [Abstract] [Full Text]  
  • Gulick, R. M. (1998). HIV Treatment Strategies: Planning for the Long Term. JAMA 279: 957-959 [Full Text]  
  • Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., Peeters, F., Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., Pauwels, R. (1998). A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrob. Agents Chemother. 42: 269-276 [Abstract] [Full Text]  
  • McDougall, B., King, P. J., Wu, B. W., Hostomsky, Z., Reinecke, M. G., Robinson, W. E. Jr. (1998). Dicaffeoylquinic and Dicaffeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase. Antimicrob. Agents Chemother. 42: 140-146 [Abstract] [Full Text]  
  • McDonald, C. K., Kuritzkes, D. R. (1997). Human Immunodeficiency Virus Type 1 Protease Inhibitors. Arch Intern Med 157: 951-959 [Abstract]  
  • Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., Furfine, E. S. (1996). Human Immunodeficiency Virus. MUTATIONS IN THE VIRAL PROTEASE THAT CONFER RESISTANCE TO SAQUINAVIR INCREASE THE DISSOCIATION RATE CONSTANT OF THE PROTEASE-SAQUINAVIR COMPLEX. J. Biol. Chem. 271: 33231-33235 [Abstract] [Full Text]  
  • Schock, H. B., Garsky, V. M., Kuo, L. C. (1996). Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials. COMPENSATORY MODULATIONS OF BINDING AND ACTIVITY. J. Biol. Chem. 271: 31957-31963 [Abstract] [Full Text]  
  • Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., Livingston, D. J. (1996). Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants. J. Biol. Chem. 271: 17979-17985 [Abstract] [Full Text]  
  • Menéndez-Arias, L., Weber, I. T., Oroszlan, S. (1995). Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases. J. Biol. Chem. 270: 29162-29168 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»